|
Adelaide, Australia & North Carolina, USA, Oct 19, 2023 - (ACN Newswire) - Avance Clinical, the Australian and North American market-leading CRO for biotechs, was asked to present their GlobalReady drug development solution to more than 45 Korean biotechs and pharmaceutical companies in Seoul, Korea last week as part of a special symposium at KoNECT Korea Conference.
Dt & SanoMedics Chairman, Charles Park (Park, Chae Gyoo) and Avance Clinical CEO Yvonne Lungershausen co-hosting the Global Clinical Trial Strategy Symposium in Korea last week.
Avance Clinical’s Korean CRO partner Dt & SanoMedics initiated the Global Clinical Trial Strategy Symposium and invited Avance Clinical to co-host.
The Avance Clinical team, including CEO Yvonne Lungershausen, and Vice President, Commercial Business Development, Liahna Toy discussed drug development options including conducting clinical trials across South Korea, Australia, New Zealand, and the United States to support fast tracking clinical trial development programs.
Yvonne Lungershausen said Avance Clinical offers two critical solutions for biotechs.
“Avance Clinical in Australia can maximise the 43.5% rebate on clinical trial spend, and in the United States can provide high quality trials following the FDA pathway. Both approaches were received as attractive propositions for biotechs wanting to maximise their data captured and conserve funding,” she said.
“Our Avance Clinical teams in Australia and the United States offer world-class quality data and cultural alignment for Korean biotech clients designed to make their drug development programs seamless and successful.”
“Avance Clinical’s study data is accepted by all the main regulatory authorities including the MFDS and FDA; and conversely the Therapeutic Goods Administration (TGA) in Australia recognises data generated in Korea.”
Yvonne Lungershausen thanked Korean CRO partner Dt & SanoMedics for arranging the Global Clinical Trial Strategy Symposium.
“This was an impressive group of biopharma companies and we are extremely excited to be part of their clinical program as they expand to the United States.”
“Thank you to Chairman of the Dt&C group, Charles Park and Yujin Lee, Vice-President of Dt & SanoMedics, and the entire team for welcoming and hosting Avance Clinical in South Korea.”
Dt & SanoMedics VP Yujin Lee said the partnership with Avance Clinical has been further strengthened with the team providing valuable international drug development strategies for the Korean biotech community.
“We are pleased to introduce the Avance Clinical team because we know they stand for quality. Importantly, they have the experience and track-record especially in the United States which is where most biotechs will be conducting their later phase trials.”
“We believe this has been an important visit which has enabled us to enhance our partnership and actively help Korean companies enter the US and Australian pharmaceutical markets,” she said.
About Avance Clinical
Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.
Award-winning CRO for Biotechs
Avance Clinical has been recognised for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech's award, for its continuous exceptional performance.
Pre-clinical through to Phase I and Beyond
Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia and highly qualified sites and networks within the United States. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.
www.avancecro.com
Media Contact:Avance ClinicalKate Thompsonmedia@avancecro.com
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network. |
|
|
Latest News 韓国の主要人物・金載德氏がMOVA Chain支援を表明、エコシステム発展が新段階へ 韓国・ソウル, Dec 13, 2025 - (JCN Newswire) - 韓国のブロックチェーンおよびデジタル経済分野で新たな動きが報じられている。政治、社会団体、メディア、国際交流など多分野で活動する金載德（Kim Jae-duk）氏が、ブロックチェーン連盟会長およびMOVA Chainエコシステム支援者として関与を開始し、MOVAプロジェクトが韓国で広く注目されている。 首隻山水實景表演概念股 印象大紅袍啟動香港公開募股 香港, Dec 12, 2025 - (ACN Newswire) - 中國領先的文旅服務企業 – 印象大紅袍股份有限公司 （新三板股票代碼：870608）（「公司」或「印象大紅袍」）今日宣佈啟動香港公開發售計劃（「香港公開發售」），計劃於香港聯合交易所有限公司（「香港聯交所」）主板上市（股份代號：2695）。 首只山水实景表演概念股 印象大红袍启动香港公开募股 香港, Dec 12, 2025 - (ACN Newswire) - 中国领先的文旅服务企业 – 印象大红袍股份有限公司 （新三板股票代码：870608）（「公司」或「印象大红袍」）今日宣布启动香港公开发售计划（「香港公开发售」），计划于香港联合交易所有限公司（「香港联交所」）主板上市（股份代号：2695）。 雲頂新耀與海森生物簽署商業化服務協議及授權許可協議 推動商業化協同與多領域佈局 香港, Dec 12, 2025 - (ACN Newswire) - 雲頂新耀（Everest Medicines，HKEX 1952.HK）于2025年12月11日，宣佈其全資附屬公司雲頂新耀醫藥科技有限公司（以下簡稱：「雲頂新耀醫藥科技」）已與海森生物醫藥有限公司（以下簡稱：「海森生物」）簽署兩項戰略合作協議，包括商業化服務協議以及授權許可協議。  云顶新耀与海森生物签署商业化服务协议及授权许可协议 推动商业化协同与多领域布局 香港, Dec 12, 2025 - (ACN Newswire) - 云顶新耀（Everest Medicines，HKEX 1952.HK）于2025年12月11日宣布，其全资附属公司云顶新耀医药科技有限公司（以下简称："云顶新耀医药科技"）已与海森生物医药有限公司（以下简称："海森生物"）签署两项战略合作协议，包括商业化服务协议以及授权许可协议。 國泰海通成功發行非銀金融機構首單上海自貿離岸債 香港, Dec 12, 2025 - (ACN Newswire) - 12月11日，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK）擔任配售代理牽頭行，協助國泰海通金融控股有限公司（以下簡稱「國泰海通金控」）成功發行非銀金融機構首單上海自貿離岸債，發行規模為5億元離岸人民幣，期限為364天，票面利率為1.8%，由上海清算所登記託管。 国泰海通成功发行非银金融机构首单上海自贸离岸债 香港, Dec 12, 2025 - (ACN Newswire) - 12月11日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）担任配售代理牵头行，协助国泰海通金融控股有限公司（以下简称"国泰海通金控"）成功发行非银金融机构首单上海自贸离岸债，发行规模为5亿元离岸人民币，期限为364天，票面利率为1.8%，由上海清算所登记托管。 国泰君安国际荣登《商业周刊》彭博绿金2026值得关注榜 - 绿色金融机构榜单 香港, Dec 11, 2025 - (ACN Newswire) - 近日，《商业周刊》彭博绿金2026值得关注榜单在上海正式发布。国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）凭借在绿色金融领域的卓越表现与创新实践，成功入选"绿色金融机构榜单"。 康哲藥業（0867）抗急性缺血性卒中創新藥注射用Y-3中國NDA獲受理 深圳, Dec 11, 2025 - (ACN Newswire) - 康哲藥業控股有限公司（"康哲藥業"）欣然宣佈，1類新藥注射用Y-3（擬定中文通用名：注射用洛貝米柳）（"注射用Y-3"或"產品"）新藥上市許可申請（NDA）已於2025年12月11日獲得中國國家藥品監督管理局（NMPA）受理。 |
|